Allogene Therapeutics advances cell therapy pipeline in latest business update

Allogene Therapeutics advances cell therapy pipeline in latest business update
Allogene Q2 2026 business update

Allogene Therapeutics has published its corporate update for the second quarter of 2026, outlining recent business advances.

The update includes progress in its allogeneic CAR-T and cell therapy portfolio, reflecting continued efforts to innovate in the cell therapy field. Investors and stakeholders can access the full report through the company’s official channels.

Earlier this year, Allogene Therapeutics gained FDA RMAT and Fast Track designations for its allogeneic CAR-T therapy cema-cel in LBCL, according to a previous report here. The company also launched a trial testing a new first-line consolidation method to assess relapse risk in LBCL patients here. Both initiatives marked key steps in advancing its cell therapy pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.